Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Centocor briefing document for Ustekinumab, submitted to FDA
Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.
Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis.
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Demyelination affects temporal aspects of perception: An optic neuritis study.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
The Brief Repeatable Battery: psychometrics and normative values with age, education and gender corrections in a Serbian population.

Pages